Brief: Aprea Therapeutics Announces Clinical Hold On Lymphoid Malignancy Program
12/08/2021 11:05
Aug 12 (Reuters) - Aprea Therapeutics Inc APRE.O :
* APREA THERAPEUTICS ANNOUNCES CLINICAL HOLD ON LYMPHOID
MALIGNANCY PROGRAM
* APREA THERAPEUTICS INC - U.S. FDA PLACED CLINICAL HOLD ON
CLINICAL TRIAL EVALUATING EPRENETAPOPT WITH ACALABRUTINIB OR
WITH VENETOCLAX AND RITUXIMAB
* APREA THERAPEUTICS INC - FDA'S CONCERNS REFERRED TO SAFETY
AND
EFFICACY DATA FROM PHASE 3 MDS CLINICAL TRIAL
Source text for Eikon: ID:nGNX69Gjc6
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing